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Mcsulergine displays approximately 50-fold higher affinity for the rat 5-HT2 receptor than for the human receptor. Comparison of the deduced 
amino acid sequences of cDNA clones encoding the human and rat S-HTI receptors reveals only 3 amino acid ditTerences in their transmcmbrane 
domains. Only one of ~hcsc differences (Scr + Ala at position 242 of TMS) is near to regions implicated in ligund binding by G protein-coupled 
h-ceptors, We investigated the effect of mutating SW’.” OT the human 5-HT? receptor to an Ala residue as is found in the rat clone. Both 
[‘H]mesi;!erginc binding and mesulcrgine competition of [>H]ketanscrin binding showed high affinity for rat membranes and the mutant human 
clone but low aflinity for the native human clone, in agreement with previous tudies of human postmortem tissue. These studies uggest that a 
single naturally occtirring amino acid change between the human and the rat 5-HT2 receptors makes a major contribution to their pharmacological 
differences. 
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1. INTRODUCTION 
Many serotonin receptor subtypes have now been 
cloned from more than one species. This information 
allows one to examine the properties of isolated recep- 
tor subtypes to determine which amino acid sequences 
impart species-specific pharmacology to various recep- 
tors. In many cases, such as the human [I] and rat [2] 
serotonin 5-HT,, receptors, or human and dog 5-HTID, 
receptors [33 similar pharmacological binding proper- 
ties were reported for transfected clones obtained from 
either species. In other cases, dramatic pharmacological 
differences exist for species homologues of the same 
receptor. For example, the 5-HTln receptor has been 
shown to be the rat analog of the human SHT,, recep- 
tor [4], yet these two homologous genes, which are 93% 
identical in overall amino acid sequence, display mark- 
edly different pharmacological binding properties. 
In this report we studied the species differences be- 
tween the rat and human S-HT? receptors. Certain li- 
gands, most notably mesulergine [S, 63, bind with differ- 
ent affinities to the rat 5-HTz receptor compared to the 
human 5-HTz receptor. We cloned the human 5-I-IT? 
receptor and expressed this receptor, and a mutant re- 
ceptor with a single amino acid substitution, in mam- 
A human brain stem cDNA iibrary provided by Stratagene (La 
Jolla. CA) was screened using a randomly primed probe made by 
rcvcrse transcription oTSp6gancra~ed RNA made from the rat 5HTIc 
receptor gent. Hybridization was performed at GO°C in a solution 
containing 5x SSC (Ix SSC is 0.15 M sodium chloride, 0.015 M 
sodium citrate), 2x Denhardt’s (0.02% polyvinyl-pyrrvolidone, 0.02% 
Ficoll. und 0.02% bovine serum albumin), IO0 mM sodium phosphate 
pH 8,0,25mM EDT& 0. I % sodium dodccyl sulfate (SDS) and lOOp& 
ml of sonicatrd salmon sperm DNA. The filters were washed at 60°C 
in 0.1x SSC containin 0.1% SDS and exposed at -7OOC to Kodak 
XAR lilm in the prcscncc of an intensifying screen. Lambda phage 
hybridizing to the probe were plaque purified and plasmid DNA (in 
the vector pBlucscript) self-excised from the lambda vector (lambda 
ZAP). 
Correspondence ddress: P. Martig, Synaptic Phurmaceutical Corpo- One clone from the screening of the human brainstem library dis- 
ration , 215 College Road, Paramus, NJ 07652. USA. Fnx: (I ) (10 I ) played high homology to the published sequence ofa rat 5-HT. reccp- 
3G I-0623. lor clone [S]. This clone did not contain the entire coding region. 
malian cell lines. Comparison of mesulergine binding to 
these preparations and to native rat and human cortical 
membranes uggests that the different binding proper- 
ties of rat and human 5-MT2 receptors are due to 
changes at a single amino acid residue. 
2. MATERIALS AND METHODS 
The rat 5-HT,, gene was used as a probe for the isolation of the 
human 5-l-IT2 gene. The ral 5-HT,, receptor cDNA was obtained by 
screening arat choroid plexus cDNA library (in RptlO) using oligom- 
ers complementary to the rat 5-HTIc published sequence [7]. The 
cDNA containing the entire coding region was verified by sequencing 
and subcloned in the RNA transcription vector pGEM1 (Promcga 
Biotech; Madison, Wl). 
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“P-labelled oligomcrs complcmcntary to the 5’ end of this clone wcrc 
used lo screen a human temporal cortex cDNA library (Slratagenc. 
La Jolla, CA). Four independent clones were isolated, and one, desig 
nated 613. containing the entire coding region was sclbrtcd for further 
studies. The coding region from 6B was subcloned into the mammal- 
ian expression VCCLO~ pM05. The human 5.HT, receptor has also been 
cloned by Saltzman et al. 191. Our sequence isessentially identical to 
this published sequence. 
2.2. DNA sequrrhzg 
Nucleotic sequence analysis was done by the Sangcr dideoxy nucle- 
elide chain-termination method [IO] on denatured ouble-stranded 
plasmid templates [I I] using Scqucnasc (US Biochemical Corp.. 
Cleveland, OH). 
Mutagenesis was carried out using PCR primers in which the dc- 
sired mutation was incorporated into the sequence of the primer. The 
methods used are essentially the same as that described by Duluu CI 
al. [I?]. The region of DNA mutated was flanked by lhe Sp6 and T7 
primers in the vector pGEM1. The mutant fragmuut (containing the 
mutating primer) was ligaicd along with its corresponding unmuiated 
fragment into the expression vector pM05. The mutolion was con- 
firmed by sequencing. 
To verify that the cDNA encoded a functional 5.HTz receptor, 
Cos-7 ceils \vere transiently transfecrcd using the DEAE-dcxtrao tcch- 
niquc [I 31. Subscquemly, stable cell lines were produced by colransfcc- 
tion of the plasmid PM05 containing the 5-HT2 gene with the plasmid 
PGCneo (which contains the aminoglycoside phospbotransfcrasc 
gene) into murine fibrolast LsM(TK-) cells (American Tissue Type 
Collection, Rockville. MD, Cell Line CCL I ,3). These stable transfcc- 
lions were accomplished using the calcium phosphate tccbniquc (Spe- 
cialty Media; Lavellette, NJ). Stable cell lines were not established for 
the mutant clones. Cells were sclectd by resistance IO the antibiotic 
G-418 (Gibco; I mg/ml) as previously described [14], rH]Ketnnserin 
binding was used to monitor 5-HT! receptor gene expression i  these 
clones (see below). Three OUI ofsixtcen clones displayed specific bind- 
ing of [‘Hlkctanserin. No signilicant specific binding was detected on 
pscudotransfcaed or non-transfected L-M(TK-) or Cos-7 cells at 1 or 
2 nM [“Hlkctanserin (dala not shown). 
fH]Kctanserin was used as tbc radioligand to detect expressian of 
the S-MT2 gene product in mcmbrdne fractions isolated form trans- 
fccted cells. Radiolignnd binding assays were done as previously de- 
scribed [IS] with slight modilication. Briefly, binding assays were con- 
ducted in 9G-well microtiter plates, in a tolal volume of 0.25 ml of 
buffer (50 mM Tris-HCl, 0.5 mM EDTA, IO mM MgSO,, 0.1% 
ascorbate and 10 PM pergyline, pH 7.6) containing l-2 nM [‘H]ket- 
anserin (64.9 Ci/mmol; DuPontaNEN, Wilmington. DE). Mianserin 
at I .O /lM was used to define non-specific binding. Assays were initi- 
ated by the addition of 50 ~1 of membrane homogenate (20-u) ,rrg 
protein/well). After a 20 min incubation at 37°C the assay was tenni- 
nated by filtration. Specific binding was 95% of total binding for the 
transiently transfected cells and 85% for the stable cell lines at I nM 
pH]ketanserin. Prolein was determined by the method of Bradford 
1161. 
Coml>etition studies for [‘Hlketanserin binding were performed by 
adding increasing concentrations of test drug to the reaction. IO-12 
l&and doses were used and spanned the expected I& range as deter- 
mined from lheralure values. Data were analyzed by compiiter-as- 
sisted analysis (Accufil Competition; Lundon Software; Chagrin 
Falls, OH). lClo values were converted to & values using the Cheng- 
Prusofr equaiion [ I7j. 
2.6. [JH]Mesdergit~e DCt&ng 
To dcterminc whether the clones humnn 5.HT, receptor bound 
~H]mcsulc:ginc wi\h high afinity, saturation studies were performed 
according to the method ofclosse [IB]. [‘H]Mesulcr@c [84 Ci/mmol; 
Amcrsham) was tested at concentrations between 2.0 and 400 nM for 
the human 5-HT2 clone (h5-HT2) and between 0.02 and 3.0 nM for 
the mutant 5-HTz clone (h5-HTlmu) and mt cortical mcmbrancs. 
IncubaGons \vcrc performed at37% for 60 min and the reaction was 
terminated by rapid filtration as above. 
Mianserin hydrochloride arid mesulergine were purchased from Rc- 
selrrch Biochemicals. Natick, MA. All other chemicals were of highest 
purily. purchased from commercial sources. 
3. RESULTS 
3.1. P~~artrtucological properties of the transfecred 
iwtm T-HT, receptor 
Membranes collected from cells stably transfected 
with a human S-MT, receptor cDNA (hS-HT2) were 
found to bind [3H]ketanserin saturably, reversibly, and 
with high affinity, as previously reported [IS]. Com- 
pounds reported to differ in affinity for the human YS 
the rat S-MT2 receptor were selected for competition 
studies. Apparent inhibition constants (Ki values) from 
the analysis of competition experiments is shown in 
Table I, in comparison to values obtained in human and 
rat cortex. These data indicate that the cloned gene 
encoded a 5-HT2 receptor and that the pharmacological 
properties of this cloned human receptor assayed in a’ 
heterologous expression system match that reported for 
the 5-HT2 receptor assayed in homogenates of human 
post-mortem cortical tissue. 
The most significant difference between the binding 
properties of human and rat S-HTz receptors has been 
reported to be their affinities for mesulergine [S]. Mesul- 
ergine competition of [3H]ketanserin binding to the 
Table I 
Competition experiment for [‘Hlkctanserin labeled human 5-NT: rc- 
ceptor stably transfccted into L-M (TK-) cells as compared with 
published values for the native human and rat 5.HTz receptor 
Drug Kj (nM) K, (nM)’ 
Human Human cortex Rat cortex 
Spiprone 1.1 f 0.07 O.Qb 0.29b 
5-HT 598 4 52 174 79 
desulerginc 129 & 7.9 151 4.7 
Ritanserin I.! f 0.16 I.3 7.2 
Cyprohcptadine 2.9 t 0.10 6.3 I.8 
Methysergide 3.3 r 0.50 5.2b 0.54b 
(+)-Butaclamol 2.3 * 0.38 I.? 2.4’ 
ggazine 
2.866 Zc 228 8,128 21,575 
1,771 f 85 3,802 1,549 
(-)-Butaclamol 3.88 I & 868 51Oh 1,831’ 
5.MT 513f29 235 240 
Each value is the mean 2 S.E.M. of at least 3 independent trial runs 
in triplicate. 
” Hoyer et al. [6). 
’ Schotte t al. [20]. 
E Lyon et al. [21]. 
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Fig. I. Amino acid sequence of the putative fifth transmembmne 
domain of serotonin, adrenurgic and dopamine receptors. Receptor 
subtypes are shown from the following species: h. human; r, rat; hm, 
hamster. Comparison of residue 143 (Serz”z of the human 5-HT1 rcccp- 
tor is shown by shading to the corresponding residue found in other 
scrotonin receptors (alanine) and to adrcncrgic and dopamine recep- 
tors (serine). 
cloned human receptor (hS-HT2) displayed low affinity, 
in agreement with previous studies in human cortex 
(Table I). We also used [‘Hlmesulergine as a radioligand 
to directly measure the affinity of this drug for the 
cloned human and native rat 5-HT2 receptors. In con- 
trast to the native rat 5-HT2 receptor, which exhibits 
high affmity binding of [jH]mesulergine, we were unable 
FEBS LETTERS Allgus 1992 
to detect any high affinity binding to the cloned human 
receptor. Using increasing concentrations of [3H]mesul- 
ergine ranging from 2.0 to 400 nM, only a low affinity, 
high capacity binding site was detected. 
We were interested in determining which specific 
amino acid residues were responsible for the divergent 
pharmacology between the rat and human 5-HT2 recep- 
tors. We reasoned, by analogy to the model for ligand 
binding to adrenergic receptors [19], that the amino 
extracellular and carboxy cytoplasmic sequences of the 
rat and human 5-HTI receptors were unlikely to signif- 
icantly affect ligand binding specificities. The trans- 
membrane domains of these receptors exhibit only 3 
amino acid sequence differences: at residue 82 (Thr + 
Ala), at residue 1 SO (11~ + Val), and at residue 242 (Ala 
+ Ser). Residue 242 appeared to be significant because 
it occurred in a transmembrane r gion (TM 5) at a site 
previously implicated in ligand binding to adrenergic 
receptors [19], and involved a change from a non-polar 
amino acid to a polar amino acid. Furthermore, this 
specific position contains a Ser residue in both the 
human 5-HT, receptor and in all adrenergic and 
dopamine receptors reported to date (Fig. 1). In these 
catecholamine r ceptors, this serine residue is believed 
to form a hydrogen bond to a ring hydroxyl of the 
catechol neurotransmitter [19]. Since the indole ring of 
serotonin does not contain a ring hydroxyl in the corre- 
sponding position, the role of this serine residue in the 
human 5-HT, receptor is unclear. Nevertheless, this 
serine is located near to the ligand binding site and was 
expected to contribute to its &and binding properties. 
3.3. Mirkiget~esis wsulrs 
We made a site-specific mutation tit residue f-42 of the 
human serotonin 5-HT, receptor to convert t’;le hu_nan 
residue (Ser) to the residue found in the rat receptor 
(Ala). The nucleotide and deduced amino acid sequence 
comparison between the rat, human (h5-HT2) and mu- 
tant receptor (h5-HT2mu) genes is depicted in Fig. 2. 
The human 5-HT, mutant receptor in which Seti’? was 
Sequence comparison of 5-HT, receptor sequence in tfansmembrane V. 
Y 




h5-mamu (MUTANT INMAN) TCT T&P 
v 
GTG G& T% 
F P 
TTC *L CCC Tk 
S F Y A F F T 
r5-HP2 (NORMI& RAT) 
P z 
TCT TTT GTG GCA TTT TTC ATC CCC CTA 
Fig. 2. Nucleotide and deduced amino acid sequences of the human, rat and mutant 5.HT, rcccptorr in transmembrane domain V. h5-HTZ=normal 
human receptor sequence; r5-HTZ=normnl rat receptor scqucnce; h5-HTZmu=human receptor scqucncc mutated from SeP2 to A1a2’2, 
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Table I1 
Kinetic parameters of the pH]mesulerSine binding to the cloned 
human S-HT2 receptor expressed in L-M(TK-) cells, comparison with 
the human mutant 5-HT, receptor expressed inCos-7 cells and to the 
n&e rat 5-HTI receptor 
Mcmbrancs Kd (nM) &,, (pmo)lmg 
protein) 
Human 5-HTr receptor (h5-HT2) 174k26 5.7 + 0.82 
Human S-HT? mutant (hS-HT2mu) 2.6 f 1.1 1.6 zt 0.81 
Rat cortex 3.0 r 0.9G 1.1 TO.23 
Values for the dissociation constant (K,) and site density (B,,,J arc 
reported. Each value is the mean + S.E.M. for 3 independent trial 
runs in triplicate. Saturation curves, each containing 12 diffcrcnt con- 
centrations of radioligand, were run in parallel. Parameters were cal- 
culated by computer-assisted non-linear regression analysis (Accufit, 
Lundon Software). 
changed to Ala (h5-HTZmu) displayed at GO-fold higher 
affinity for [3H]mesulergine than the native human re- 
ceptor (h5-HT2) (Table II). The aflinity of mesulergine 
for the mutant receptor was very close to that deter- 
mined for rat cortical membranes in this study (Table 
I). Similarly, when unlabelled mesulergine was used to 
compete for [3H]ketanserin binding, the human 5-HT? 
clone h5-HT2 displayed approximately 30-fold lower 
affinity for mesulergine compared to the mutant h5- 
HT2mu clone or the rat cortical membranes. Mean Ki 
values (apparent dissociation constants} for unlabelled 
mesulergine were as follows: S-NT? clone: I29 -1- 7.9 nM 
(n=4); mutant hS-MT2mu clone: 4.2 * 2.0 nM (~3); rat 
cortex: 4.5 t- 0.22 nM (rs=3). These data indicate that 
changing a single key amino acid residue of the human 
S-I-IT, clone to the residue contained in the rat clone is 
sufficient to change its pharmacological binding proper- 
ties for mesulergine to that of the rat receptor, even 
though all other amino acid differences between the 
clones remain unaltered. This suggests that Set-“’ is the 
most important determinant of rat vs. human pharma- 
cological binding properties in this receptor. 
4. DISCUSSION 
We have cloned and expressed the gene encoding a 
human S-I-IT?_ receptor. Binding studies on transfected 
cell membranes upport the interpretation that this 
clone is a S-HT? receptor, with properties that match 
previous binding studies on post-mortem human corti- 
cal tissues. Several different chemical classes of corn- 
pounds displayed affinities for the transfected human 
receptor which were close to human cortex values and 
clearly different from values in rat cortical membranes. 
This species difference in S-MT? receptor binding prop- 
erties is particuiariy evident for mesulergine, which dis- 
plays high affinity for the rat but not Tar the human 
receptor [63. As has been reported for the native human 
5-HT2 receptor [5], we observed that [“H]mesulergine 
could not be used to label the transfected human recep 
tor, and that unlabeled mesulergine displayed low af- 
finity in competition binding experiments. It has been 
speculated that species-specific drug binding differences 
such as this could be due to factors ranging from the 
lipid composition of the membrane nvironment of the 
receptor, to possible post-mortem degradation. Our 
data strongly suggest hat the species differences in 
pharmacological binding properties of the human vs. 
rat 5-HT, receptor arise from amino acid differences in 
the protein rather than from differences in its membrane 
environment or cellular processing. 
The human and rat 5-HT2 receptor sequences are 
92% identical at the amino acid level. In the transmem- 
brane domains, the regions which appear to contain the 
ligand binding site [ 191 only three amino acid differences 
occur between the rat and human receptors. Our study 
shows that the single transmembrane amino acid dif- 
ference that occurs within a proposed ligand binding 
region (Se?) is a critical determinant of the species- 
specific pharmacological binding properties of the 5- 
MT2 receptor. We have found that mutating this residue 
of the human receptor to the amino acid found in the 
rat sequence (from Ser 3 Ala) alters mesulergine bind- 
ing such that the mutated human S-HTI receptor now 
resembles the rat S-MT1 receptor. The other 40 amino 
acids which differ between the rat and human receptors 
do no appear to be critical in determining the species- 
specific binding properties of the 5-HT2 receptor for 
mesulerginc. The fact that this single amino acid substi- 
tion increased rather than decreased the affmity of the 
receptor for mesulergine seems to rule out nonspecific 
effects (such as 3 delocalized conformational change) as 
a mechanism and stongly suggests that this residue 
forms a component of the serotonin and drug binding 
sites. 
In comparing our results to the original ligand bind- 
ing model of Strader et al. [19], it is interesting to note 
that the presence of a Ser residue at position 242 of the 
human 5-HT2 receptor would have led to the prediction 
that the human 5-HT, receptor should bind catechols 
with high affinity, since this residue is in the position 
proposed for interactions with the ring hydroxyl of a 
catechol neurotransmitter. We were unable to detect 
any high affinity binding ofnorepinephrine to the trans- 
fectcd human 5-HTz receptor (data not shown). In addi- 
tion. the pharmacological binding properties of the 
human 5-HT? receptor clearly distinguish it from cat- 
echolamine receptors. This suggests hat the presence of 
a Ser residue at position 242 (such as is found in all 
catecholaniinergic receptors) is not of itself a sufficient 
condition to impart high affinity for catecholaminergic 
ligands, and that additional factors, such as critical con- 
formational positioning of this residue, may piay im- 
portant roles in the l&and binding properties of the 
receptor. Recently. a group of insect serotonin receptors 
were reported which further illustrate this principal. 
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The dro-1 receptor, like the human 5-HT2 receptor, 
contains a Ser residue at an analagous position in TM% 
while the dro-2A and dro-2B receptors contain a homol- 
ogous residue, Thr, in this position [22]. All three of 
these Drosophila serotonin receptors display serotoner- 
gic rather than catecholaminergic binding and response 
properties. 
In summary, our results uggest that residue Scr’“’ of 
the serotonin S-HT2 receptor forms a component of the 
ligand binding site and exerts a strong influece on drug 
binding afhnities. The fact that the human S-HT? recep- 
tor displays human pharmacological binding properties 
when expressed in a rodent cell line suggests that the 
amino acid sequence of a receptor is more important 
than the environment in which a receptor is more im- 
portant than the environment in which a receptor is 
expressed in determining drug binding affinities. Fi- 
nally, these site-specific mutagenesis results imply that 
the pharmacological differences between the rat and 
human receptors are due to a very small change in the 
sequence, most of which can probably be attributed to 
a single amino acid. 
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